Related Experiment Videos
The effect of glipizide on HDL and HDL subclasses
Diabetes Research (Edinburgh, Scotland)
|June 1, 1986
Summary
Glipizide treatment did not alter high-density lipoprotein (HDL) subclasses in patients with type 2 diabetes. This study found no adverse effects of glipizide on HDL levels or other lipid profiles.
Area of Science:
- Endocrinology
- Metabolic Disorders
- Lipid Metabolism
Background:
- Type 2 diabetes is associated with dyslipidemia, including altered high-density lipoprotein (HDL) levels.
- Understanding the impact of common diabetes medications on lipid profiles is crucial for patient management.
Purpose of the Study:
- To prospectively evaluate the effects of glipizide on HDL subclass levels (HDL2 and HDL3) in patients with type 2 diabetes.
- To assess the impact of glipizide on glycemic control and other lipid parameters.
Main Methods:
- Prospective evaluation of 9 patients (7 women, 2 men) with type 2 diabetes treated with glipizide.
- Measurement of total HDL, HDL2, HDL3, blood glucose, HbA1c, triglycerides, and cholesterol levels before and during treatment.
Main Results:
- Glipizide treatment did not significantly change total HDL, HDL2, or HDL3 levels.
- Mean blood glucose and HbA1c levels remained unchanged, though 5 individuals showed improvement.
- Triglyceride and cholesterol levels were unaffected by glipizide.
Conclusions:
- Glipizide does not appear to adversely affect HDL lipoprotein levels in patients with type 2 diabetes.
- The study suggests glipizide is safe concerning HDL metabolism in this patient group.